-+ 0.00%
-+ 0.00%
-+ 0.00%

Zymeworks Announces $125M Buyback Plan

Benzinga·05/14/2026 20:25:03
Listen to the news

Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that its Board of Directors has authorized a 2026 share repurchase program under which the Company may repurchase up to $125.0 million of its outstanding common stock, par value $0.00001 per share.